Stem Cell Stocks Jump on New Congressional Promise

by H.S. Ayoub
BioHealth Investor



Stem cell stocks gained big time on Thursday as the new U.S. congress was set to take helm. The new Domocratic agenda promises to ease restrictions on embryonic stem cell research funding imposed by the Bush administration.

While Bush is expected to veto the new legislation, critics believe there is enough push in the Senate to over-ride the veto.

It is exptected that under a Democratic environment biotech stocks in general should perform well over the next few years, especially contraversial areas such as embryonic stem cell research.

Shares of Geron (GERN), StemCells (STEM), Aastrom (ASTM), Thermogenesis (KOOL), LifeCell (LIFC), Advanced Cell Technology (ACTC), Viacell (VIAC). Cryo-Cell (CCEL), and Cord Bloog America (CBAI) all gained on the day.

Aastrom, StemCells, Cord Blood America and Advanced Cell Technology all gained by double digit percentage points.

__________

Related articles:
- Low Cost Drugs; Stem Cell Research on New Congress Agenda
- Geron's Research Arsenal: Stem Cells, Cloning, Cancer
- StemCells Inc. Transplant Patient Heads Home
__________